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Abstract
This study demonstrates that two orthogonal events regulate integrin αIIbβ3’s interactions with
fibrinogen, its primary physiological ligand: (1) conformational changes at the αIIb–β3 interface
and (2) flexibility in the carboxy terminus of fibrinogen’s γ-module. The first postulate was tested
by capturing αIIbβ3 on a biosensor and measuring binding by surface plasmon resonance. Binding
of fibrinogen to eptifibatide-primed αIIbβ3 was characterized by a kon of ~2 × 104 L mol−1 s−1
and a koff of ~8 × 10−5 s−1 at 37 °C. In contrast, even at 150 nM fibrinogen, no binding was
detected with resting αIIbβ3. Eptifibatide competitively inhibited fibrinogen’s interactions with
primed αIIbβ3 (Ki ~ 0.4 nM), while a synthetic γ-module peptide (HHLGGAKQAGDV) was only
weakly inhibitory (Ki > 10 µM). The second postulate was tested by measuring αIIbβ3’s
interactions with recombinant fibrinogen, both normal (rFgn) and a deletion mutant lacking the γ-
chain AGDV sites (rFgn γΔ408–411). Normal rFgn bound rapidly, tightly, and specifically to
primed αIIbβ3; no interaction was detected with rFgn γΔ408–411. Equilibrium and transition-state
thermodynamic data indicated that binding of fibrinogen to primed αIIbβ3, while enthalpy-
favorable, must overcome an entropy-dominated activation energy barrier. The hypothesis that
fibrinogen binding is enthalpy-driven fits with structural data showing that its γ-C peptide and
eptifibatide exhibit comparable electrostatic contacts with αIIbβ3’s ectodomain. The concept that
fibrinogen’s αIIbβ3 targeting sequence is intrinsically disordered may explain the entropy penalty
that limits its binding rate. In the hemostatic milieu, platelet–platelet interactions may be localized
to vascular injury sites because integrins must be activated before they can bind their most
abundant ligand.
Regulated fibrinogen binding to some 80000 αIIbβ3 integrins resident on human blood
platelets is essential to normal hemostasis and aberrant in thrombosis (1, 2). Despite their
crucial role in human health and disease, defining the molecular mechanisms that shift
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αIIbβ3 from a quiescent heterodimer to a hemostatically active receptor remains a challenge
(3–6). Recent evidence indicates that intracellular integrin activation involves talin binding
to the β3 cytodomain, triggering subunit shifts that ultimately extend the ectodomain (7, 8).
Advances in structural biology also support outside-in signaling models in which subtle
conformational changes linked to ligand binding at the αIIb β-propeller–β3 I domain
interface (6, 9, 10) are allosterically coupled to rearrangements of the receptor’s
transmembrane segments and cytodomains (11–14). Pharmaceutical integrin ligands present
a twist: they bind to resting αIIbβ3, but it then populates an active form that persists for
hours after their dissociation (15, 16).
While platelet stimulation is clearly prerequisite for fibrinogen binding, affinity estimates
(Kd) for this abundant protein (plasma concentration of ~10 µM) range from <100 nM (17–
19) to >2 µM (20, 21). Studies incorporating αIIbβ3 in lipid vesicles yielded Kd values from
5 to 15 nM (22–24), but uncertainty about the receptors’ activation state raises new
questions. Subsequent reports using solid-phase binding assays indicated that fibrinogen
binds rapidly (kon ~ 8 × 105 L mol−1 s−1) (25) and tightly (Kd ~ 60 nM) (26) to immobilized
αIIbβ3. However, those affinity-purified integrins were isolated by a process that selects for
preactivated receptors (27, 28), so binding regulation was not addressed. In contrast, Du et
al. (29) demonstrated that αIIbβ3 acquired the ability to bind fibrinogen (Kd ~ 50 nM)
following overnight incubation with, and then washout of, synthetic peptide GRGDSP or
HHLGGAKQAGDV,1 albeit at a large molar excess.
Biophysical studies subsequently revealed multistep fibrinogen binding kinetics and raised
new questions. The pioneering surface plasmon resonance (SPR) studies of Huber et al. (30)
illustrate a quandary. Their biosensor-immobilized integrins only reproducibly interacted
with fibrinogen after several cycles of surface regeneration with an RGD peptide. That fits
with our observation that RGD peptides shift the initially resting receptor to an open
conformation (31). They reported a rapid initial on rate kon of ~3 × 105 L mol−1 s−1 and a Kd
of 165 nM (30). Muller et al. (32) described total internal reflection fluorescence
measurements with unstimulated αIIbβ3 reconstituted in lipid bilayers. They found a slower
kon of ~4 × 104 L mol−1 s−1, for the initial binding event but a smaller Kd of ~50 nM; slower
formation of an irreversible complex followed. In contrast, Pesho et al. (33) fit their SPR
data to a 1:1 binding model for fibrinogen’s interactions with RGD-purified αIIbβ3
covalently coupled to biosensors. They obtained a kon of ~3 × 105 L mol−1 s−1 and a much
tighter Kd of ~3 nM. To resolve the relationship between integrin activation and the rate or
affinity of fibrinogen binding, we purified αIIbβ3 in a resting conformation (34) that can be
modulated by transient exposure to a priming ligand prior to delivery of a macromolecule
for SPR binding studies (16).
The fibrinogen (AαBβγ)2 molecule is rich in potential integrin recognition sites, with classic
RGD sequences midway through the α-chains’ coiled-coil regions and on their carboxy-
terminal segments. However, fibrinogen molecules with RGE substitutions at Aα 95–97 or
Aα 572–574 supported aggregation of ADP-stimulated platelets as effectively as plasma
fibrinogen (35) or normal recombinant fibrinogen (36). Fibrinogen’s γ-chains also have a
unique αIIbβ3 targeting sequence, HHLGGAKQAGDV (37, 38). The plasma fibrinogen
variant (AαBβγ′)-(AαBβγ), which lacks that sequence on one of its γ-chains, exhibited only
half-maximal activity in platelet aggregation and fibrinogen binding assays (35, 39).
Likewise, recombinant (AαBβγ′)2 showed a markedly decreased level of platelet binding
1Abbreviations: HSCM, pH 7.4 buffer containing 0.13 mol/L NaCl, 0.01 mol/L HEPES, 0.001 mol/L CaCl2 and 0.001 mol/L MgCl2;
HSCM-OG, HSCM buffer with 0.03 mol/L n-octyl-β-D-glucopyranoside; HSCM-T, HSCM buffer with 0.01% Tween; RU, response
units; SPR, surface plasmon resonance; HHLGGAKQAGDV, synthetic peptide L-histidiyl-L-histidyl-L-leucyl-glycyl-glycyl-L-alanyl-L-
lysyl-L-glutamyl-L-alanyl-gylcyl-L-aspartyl-L-valine.
Hantgan et al. Page 2













(40), and a recombinant fibrinogen variant with its γ-chain AGDV sites deleted (rFgn
γΔ408–411) failed to support platelet aggregation (36, 41). In contrast, another recombinant
fibrinogen variant with dysfunctional α-chain RGE sites and deleted γ-chain AGDV sites
exhibited substantial clot retraction (36). Auxiliary integrin-binding sites localized to γ316–
322 (42–44) and γ370–381 (45, 46) may play special roles in mediating the adhesion of
platelets to immobilized fibrinogen and clotted fibrin.
While these observations strongly suggest that αIIbβ3–fibrin-(ogen) interactions are
mediated not by its RGD sites but rather by residues present on its γ-module, this concept
has not been rigorously tested in a purified system. Here, we present evidence from SPR
measurements performed with recombinant fibrinogen, both normal and rFgn γΔ408–411,
that residues on the carboxy terminus of its γ-module are essential for tight binding to
primed αIIbβ3. Combining our equilibrium and transition-state thermodynamic data with




Milligram quantities of highly purified αIIbβ3 were isolated from outdated human blood
platelets (Blood Bank, North Carolina Baptist Hospital, Winston-Salem, NC) by affinity and
size-exclusion chromatography in HSCM-OG buffer as previously described (47).
Anti-αIIb Cytodomain IgG
Antibody A4 was isolated by affinity chromatography from the serum of rabbits immunized
with a synthetic peptide, L-cysteinyl-L-prolyl-L-leucyl-L-glutamyl-L-glutamyl-L-aspartyl-L-
aspartyl-L-glutamyl-L-glutamyl-glycyl-L-glutamic acid, corresponding to the 10 carboxy-
terminal residues of the αIIb cytoplasmic domain as previously described (16).
Integrin Antagonists
COR Therapeutics (San Francisco, CA) provided eptifibatide [Integrilin; N6-
(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-α-aspartyl-L-tryptophanyl-
L-prolyl-cysteinamide, cyclic [1–6]-disulfide]. It was used at concentrations, determined
spectrally, that yielded >80% receptor saturation (15). Synthetic peptide L-histidiyl-L-
histidyl-L-leucyl-glycyl-glycyl-L-alanyl-L-lysyl-L-glutamyl-L-alanyl-gylcyl-L-aspartyl-L-valine
(HHLGGAKQAGDV) was prepared and characterized by the Protein Analysis Core
Laboratory of the Comprehensive Cancer Center of Wake Forest University; peptide
concentrations were determined by amino acid analysis.
Fibrinogen
Highly purified human fibrinogen, free of plasminogen and Factor XIII, was purchased from
American Diagnostica (Stamford, CT). Following reconstitution in HSCM buffer and
extensive dialysis, fibrinogen concentrations were determined spectrally (48).
Recombinant Fibrinogens
Normal and γΔ408–411 recombinant fibrinogens were synthesized in CHO cells as
described previously (41, 49). Cells were cultured in roller bottles by Biovest International
Inc./NCCC (Minneapolis, MN). Serum-free medium containing secreted fibrinogen was
harvested periodically; protease inhibitors were added, and the medium was stored at −20
°C prior to being shipped on dry ice. Recombinant fibrinogen was purified as described
previously (41, 49). Briefly, fibrinogen was precipitated from the medium with ammonium
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sulfate in the presence of a cocktail of protease inhibitors. The precipitate was resuspended
in buffer containing 10 mM CaCl2 and applied to a Sepharose 4B column coupled with the
fibrinogen-specific monoclonal antibody, IF-1. Fibrinogen was eluted from the column with
buffer containing 5 mM EDTA, dialyzed against HBS [20 mM HEPES (pH 7.4) and 150
mM NaCl] and 1 mM CaCl2 for one exchange, then extensively dialyzed against HBS, and
stored at −80 °C. The integrity of the polypeptide chains and the purity of the recombinant
protein were analyzed by SDS–PAGE under reduced and nonreduced conditions.
Surface Plasmon Resonance Spectroscopy
Measurements were performed in a Biacore T100 instrument by monitoring the changes in
response units (RU) at the biosensor surface (47). Signals from both the reference and
sample channels were collected at a rate of 10 Hz. Reagents were maintained at 25.0 ± 0.1
°C in the sample compartment; data were collected at 37, 25, or 15 °C with control to ±0.01
°C in the analysis chamber.
Purified A4 IgG, specific for the integrin αIIb carboxy-terminal segment, was covalently
coupled to the sample and reference cells of CM-5 chips to achieve a surface density of
10000–12000 RU, followed by ethanolamine blocking (16). Most experiments used primed
integrins, delivered to the sample channel at 530 ± 120 nM (n = 16) in HSCM-OG in the
presence of a 6-fold molar excess of eptifibatide. In selected experiments, resting integrins at
370 ± 170 nM (n = 2) were captured in HSCM-OG. Following the initial capture step,
samples were stabilized for 20 min, while HSCM-T buffer flowed over the chip. Note that
this step removed the octyl glucoside and priming agent (16). Similar capture levels resulted
at 37 °C with primed (300 ± 150 RU; n = 12) and resting integrins (124 ± 59 RU; n = 2).
Increased levels were obtained with primed receptors at lower temperatures: 502 ± 47 RU (n
= 2) at 25 °C and 514 ± 58 RU (n = 2) at 15 °C. To correct for differences in capture levels,
fibrinogen binding signals were normalized by the integrin capture RU for each cycle.
At each temperature, one or two start-up cycles were performed: a midrange fibrinogen
concentration (40–50 nM in HSCM-T) was delivered to the sample and reference channels,
followed by a two-step regeneration cycle, first with 3 M NaCl and then with pH 3 glycine
buffer. Next, during the binding steps, an aliquot of fibrinogen (0–150 nM) was delivered to
both flow cells at a rate of 20 µL/min for 1000 s; dissociation of the integrin–fibrinogen
complexes was then monitored for 1500 s, as HSCM-T buffer flowed over the biosensor
surface at a rate of 30 µL/min. The biosensor was regenerated and equilibrated for 300 s
with buffer prior to the next cycle.
Representative RU versus time profiles depicting integrin capture, stabilization, fibrinogen
binding (or buffer blank), and regeneration are presented in Figure S1 of the Supporting
Information. Note that αIIbβ3 bound rapidly (kon = 1.7 × 104 L mol−1 s−1) to immobilized
mAb A4 and then dissociated slowly (koff = 2.5 × 10−5 s−1) during the stabilization period.
The doubly corrected signals noted earlier account for integrin dissociation effects.
SPR Kinetic Analyses
Sensorgram responses, the difference in RU versus time between sample and reference
channels at each fibrinogen concentration, were further corrected by subtraction of profiles
obtained with a buffer blank. These doubly corrected signals (50) were then fit globally by
nonlinear regression (Biacore evaluation software) to a 1:1 binding model (47). The quality
of the fits was judged by the residuals as well as the signal-to-noise ratio (〈RU〉/√χ2). As
described in Table S1 of the Supporting Information, we also explored fitting each data set
to a bivalent analyte model, which did not significantly improve the goodness of fit. Table
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S2 of the Supporting Information shows other analyses that validate the off-rate
determinations.
Reasoning that any effects of multisite binding would be minimized at lower integrin
capture densities, we conducted a series of fibrinogen binding experiments at input
concentrations of primed αIIbβ3 of 251, 125, and 61 nM, yielding integrin capture levels of
276, 147, and 48 RU, respectively. As illustrated in Figure S2 of the Supporting
Information, comparable binding and dissociation kinetic profiles resulted at each integrin
density. While lower fibrinogen binding levels were observed at lower integrin capture
levels, each data set was described well by a 1:1 binding model. The finding that both the
forward and reverse rate constants for fibrinogen–integrin interactions were essentially
independent of the integrin capture level, over a 6-fold range, indicates that multivalent
interactions do not make a significant contribution to complex formation in our system.
Hence, we used the 1:1 binding model for all kinetic analyses in this work.
Solid-Phase Binding Assays
αIIbβ3 (34 µg/mL, 150 nM), either resting or primed by incubation with 2 µM eptifibatide
for 2 h at 37 °C, in HSCM-OG was coupled to Pierce Reacti-Bind Amine-Binding Maleic
Anhydride 96-well plates and incubated overnight at 4 °C. Fibrinogen was derivatized with
EZ-Link-Sulfo-NHS-biotin (Pierce) in a 2 h reaction in PBS at 0 °C followed by extensive
dialysis at room temperature. The degree of labeling, 7.3 mol of biotin/mol of protein, was
determined by difference spectroscopy using an avidin displacement assay (Pierce).
Biotinylated fibrinogen samples (0–30 nM) were incubated in integrin-coated or buffer
blank wells for 1 h at room temperature, followed by washing and color development steps
as previously described (16).
RESULTS
Binding of Fibrinogen to Resting and Primed αIIbβ3
SPR kinetic data demonstrated that fibrinogen bound rapidly and tightly to primed, but not
resting, αIIbβ3 receptors immunocaptured on a biosensor (Figure 1A). Fitting the data
obtained with primed αIIbβ3 and fibrinogen (5–150 nM) to a 1:1 binding model (eq 1)
yielded a close correspondence between the data (Figure 1B, filled symbols) and fitted lines
as well as a narrow distribution of residuals.
(1)
This analysis resulted in a ka of (2.19 ± 0.01) × 104 L mol−1 s−1, a kd of (7.01 ± 0.04) × 10−5
s−1, and a dissociation constant (Kd = kd/ka) of 3.20 × 10−9 M for binding of fibrinogen to
primed αIIbβ3 at 37 °C. In contrast, only negative RU versus time profiles resulted with
resting receptors (Figure 1B, empty symbols), indicating no detectable interactions even at
150 nM fibrinogen.
These findings were confirmed with a solid-phase binding assay in which biotinylated
fibrinogen (0–30 nM) was incubated with resting or primed αIIbβ3 covalently coupled to the
wells of a microtiter plate (16). Fibrinogen exhibited a hyperbolic, saturable binding profile
with the primed receptor, characterized by a 2.0 ± 0.4 nM midpoint. In contrast, signals
obtained with resting integrins exhibited a shallow, linear dependence on fibrinogen
concentration. These data indicate that fibrinogen binds ~100-fold more tightly to primed,
compared to resting, integrins (Figure S3 of the Supporting Information).
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Blocking Binding of Fibrinogen to Primed αIIbβ3
Next, we investigated the paradox that eptifibatide, the integrin antagonist that we used to
prime αIIbβ3 here and in our previous studies with PAC-1 (16), also inhibits binding of
fibrinogen to its platelet receptors (51). SPR kinetic data demonstrated that delivering
fibrinogen (100 nM) in the presence of eptifibatide (10 nM) weakened the binding signal 5-
fold compared to a control; 100 nM eptifibatide resulted in near-complete binding inhibition
(Figure 2). These data are presented as the ratio of the fibrinogen binding RU signal to the
αIIbβ3-captured RU signal to facilitate comparison between experiments.
Analysis of the complete data set with a competitive inhibition model demonstrated
eptifibatide (10–1000 nM) reduced the level of fibrinogen binding by 50% at a mole ratio of
0.08 ± 0.03 (Figure S4 of the Supporting Information). This result indicates that eptifibatide
binds ~10-fold tighter than fibrinogen to αIIbβ3. These findings were confirmed with a
solid-phase binding assay that demonstrated that eptifibatide (2 µM) reduced the level of
fibrinogen binding (0–30 nM) to near-background levels (Figure S4 of the Supporting
Information). We conclude that eptifibatide’s ability to bind tightly to αIIbβ3 (15), shifting it
from a resting to a ligand-competent conformation (16, 52), and then to dissociate rapidly
(16) contributes to its ability to both promote and block binding of fibrinogen to αIIbβ3.
Given the importance of the carboxy terminus of fibrinogen’s γ-module in promoting
interactions with αIIbβ3 (10, 53, 54), we investigated the ability of a synthetic peptide
spanning that sequence to block binding of fibrinogen to primed αIIbβ3. SPR kinetic data
demonstrated that peptide HHLGGAKQAGDV was a weak inhibitor, reducing the
magnitude of the fibrinogen binding signal by <10% at 3 µM, a 30-fold molar excess
(Figure 2 and Figure S4 of the Supporting Information). This observation fits with the
findings of Kloczewiak et al. (55), who first developed a series of γC peptides as platelet-
aggregation inhibitors. They reported an IC50 of 28 µM (165-fold molar excess) for
HHLGGAKQAGDV inhibition of binding of [125I]-fibrinogen to human platelets; maximal
inhibition of platelet aggregation required 60 µM peptide (55). Because conformational
flexibility could limit this synthetic ligand’s effectiveness, we also measured αIIbβ3’s
interactions with a recombinant fibrinogen variant lacking critical residues in its γ-module.
Recombinant Fibrinogen Binding to Primed αIIbβ3
SPR demonstrated that normal recombinant fibrinogen (Figure 3A, filled symbols) bound
rapidly and tightly to immunocaptured, eptifibatide-primed αIIbβ3 at 37 °C. Fitting the
kinetic data obtained in three experiments with normal rFgn (10, 20, 25, 30, 60, 100, 125,
and 150 nM) to a 1:1 binding model (eq 1) yielded the solid lines in Figure 3A. The resultant
kinetic parameters [ka = (2.19 ± 0.01) × 104 L mol−1 s−1, kd = (3.94 ± 0.01) × 10−5 L mol−1
s−1, and Kd = 1.80 × 10−9 M] are comparable to those obtained with highly purified human
plasma fibrinogen (Figure 1). In contrast, no binding signals were detected with rFgn
γΔ408–411, even at 100 nM (Figure 3A, empty symbols).
Excess eptifibatide fully blocked normal rFgn binding, reducing the time-dependent RU
traces to the background levels observed with rFgn γΔ408–411 (Figure 3B). Note that
excess eptifibatide had little effect on the near-baseline RU signals obtained with this
mutant. Taken together, the observations in Figure 3 indicate that both plasma and
recombinant fibrinogens use similar mechanisms to bind primed αIIbβ3 with similar
specificity.
Temperature Dependence of αIIbβ3–Fibrinogen Binding
Measuring the temperature dependence of binding of fibrinogen to primed αIIbβ3 provided
additional insights into the mechanisms that regulate these interactions. Figure 4 presents
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SPR kinetic traces obtained at 37, 25, and 15 °C with plasma fibrinogen; data are presented
as the ratio of the fibrinogen-bound to integrin-capture RU signals to facilitate comparisons.
Binding specificity was confirmed with blocking experiments performed at 100 nM
fibrinogen and 20 µM eptifibatide, which reduced the signal below background levels at
each temperature.
The solid lines in each panel were obtained by a global fit of data obtained in duplicate
experiments to a 1:1 binding model to determine the on and off rate constants and, from
them, the dissociation constant at each temperature. In each case, the narrow distribution of
residuals confirms the validity of the fits. Data obtained at 37 °C yielded a ka of (1.90 ±
0.01) × 104 L mol−1 s−1, a kd of (8.41 ± 0.03) × 10−5 s−1, and a Kd of 4.42 × 10−9 mol/L. At
15 °C, the on rate was ~2-fold slower and the off rate ~7-fold slower, yielding ~4-fold
tighter binding at the lower temperature. Intermediate values were obtained at 25 °C.
Equilibrium and Transition-State Thermodynamic Data for αIIbβ3–Fibrinogen Binding
A van’t Hoff plot (47, 56) of the temperature dependence of Kd, determined from the ratio of
the reverse and forward rate constants at each temperature, yielded a negative slope and a
near-zero intercept (Figure 5A). The resultant equilibrium thermodynamic parameters
indicated fibrinogen binding is enthalpy-driven, characterized by a ΔH° of −11.7 ± 4.4 kcal/
mol and a ΔS° of ~0. Following Eyring’s reaction rate formalism (47, 57), plotting the
temperature dependence of the rate constants (Figure 5B) yielded a set of transition-state
thermodynamic parameters. This analysis demonstrated that the transition-state free energy
barrier (ΔG°‡ = 11.8 ± 5.2 kcal/mol) is dominated by an unfavorable activation entropy (ΔS
°‡ = −28.5 ± 12.5 cal K−1 mol−1) while the enthalpic contribution (ΔH°‡) approaches 0.
These points are summarized in the reaction coordinate diagram presented in Figure 6.
DISCUSSION
Integrin Antagonist Priming Mechanisms
αIIbβ3 normally resides in a quiescent conformation (31, 34, 58) rendered inaccessible to
macromolecular ligands by an activation energy barrier (ΔG°‡ > 10 kcal/mol) (16). In
contrast, pharmaceutical integrin antagonists readily bind to the resting integrin and shift the
equilibrium toward a primed conformer that remains populated at least 90 min post-receptor
occupancy (15, 16). In this work, we showed how this conformational hysteresis provides a
window for avid fibrinogen binding.
Thanks to recent X-ray diffraction crystallographic structures of integrins, we can consider
molecular mechanisms that may explain our observations. Structural data for αIIbβ3’s
resting ectodomain (Protein Data Bank entry 3FCS) (6) as well as complexes with
eptifibatide (Protein Data Bank entry 2VDN) (6, 9) and fibrinogen’s γ-C peptide (Protein
Data Bank entry 2VDO) (10) provide insights into subtle rearrangements that accompany
ligand binding at the interface between αIIb’s β-propeller and β3’s I domain. As illustrated
in Figure 7, both these ligands occupy similar positions when bound to the αIIbβ3
ectodomain. The overall size of αIIbβ3’s ligand-binding pocket, measured as the distance
between the MIDAS Mg2+ and the salt-bridging carboxylate anion on αIIb D224, was 19.9
Å in the resting ectodomain, 19.5 Å with eptifibatide bound, and 19.7 Å with
HHLGGAKAQGDV bound. Because even the resting receptor’s pocket appears to be
sufficiently large to fit the γ-C peptide, whose zwitterions are separated by only 17 Å, we
must consider other factors to understand how fibrinogen binding is regulated.
Using the metal ion-dependent adhesion site (MIDAS) as a reference, we find that ligand
binding shifts the adjacent Ca2+ ion in the AdMIDAS site, considered a negative regulator
of adhesiveness (59), some 2–3 Å closer to the MIDAS Mg2+. Perhaps more importantly,
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that Ca2+ moves within ~4 Å of the carboxylate anion on β3 residue D251, a distance that
allows electrostatic interactions (60). As Zhu et al. (6) demonstrated, the net increased
positive charge on the MIDAS Mg2+ now favors strong ionic interactions with aspartate
carboxylates that reside ~3 Å away on both eptifibatide and fibrinogen’s γ-C peptide.
While these conformational changes are likely to be readily reversible, they are linked to
larger polypeptide chain rearrangements initiated by downward movement of β3’s α7 helix
and swing-out of its hybrid domain (9). Allosteric propagation through β3’s hybrid and PSI
domains disrupts contacts with αIIb’s thigh domain, eventually leading to an extended
integrin with a gap between its transmembrane and cytoplasmic domains (11). We propose
that the substantial conformational changes that characterize this maximally activated
integrin (14) may well account for the metastable, integrin-antagonist primed state that binds
fibrinogen (this work) and PAC-1 (16), each with nanomolar affinity.
Factors Limiting the On and Off Rates of the Fibrinogen–αIIbβ3 Complex
We demonstrated that fibrinogen binds rapidly to eptifibatide-primed αIIbβ3 (ka ~ 2 × 104 L
mol−1 s−1 at 37 °C). However, this process is~70-fold slower than the initial step in forming
an activated integrin–PAC-1 complex (16), which raises a question. What factors limit
fibrinogen binding? Structural data indicate that both macromolecular ligands recognize
αIIbβ3 through similar zwitterionic interactions (10, 61). While PAC-1’s RYD sites reside
on a loop on the IgM’s Fab domains (61, 62), the integrin targeting sequence at the carboxy
terminus of fibrinogen’s γC module exhibited no discernible electron density in crystal
structures of human fibrinogen (63), fragment D-dimer (64), or recombinant fragment D
(65). These observations suggest that the γ-chain segment on fibrinogen is highly flexible
(63, 66) and possibly intrinsically disordered (10).
In contrast, when bound to the αIIbβ3 ectodomain, synthetic HHLGGAKQAGDV displays a
unique structure (10), characterized by a tight turn that positions its lysine’s ζN+ atom within
3 Å of a carboxylate anion on αIIb’s Asp224 (Figure 7). The ligand’s aspartate is likewise
within 3 Å of the β3 MIDAS Mg2+ , providing a key source of stability. Indeed, our studies
with rFgn γΔ408–411 clearly confirm that this electrostatic contact is an essential feature of
the αIIbβ3–fibrinogen complex. The contrast between the tightly structured γC peptide–
αIIbβ3 ectodomain complex and fibrinogen’s flexible γ-chain carboxy terminus may explain
our observation that the activation free energy barrier between reactants and products is
dominated by an unfavorable entropy term (Figure 6). We propose that the conformational
entropy cost of transition-state formation strongly contributes to the relatively slow rate of
integrin–fibrinogen binding.
Once bound, fibrinogen dissociates quite slowly from the primed αIIbβ3 receptor, exhibiting
a decay time of ~200 min at 37 °C, some 70-fold slower than that of eptifibatide (16). On
the basis of our experience studying αIIbβ3’s interactions with pentameric PAC-1 (16), we
recognized that these rather slow off rates might be due to multivalent interactions with
fibrinogen, a covalent (AαBβγ)2 homodimer with an integrin targeting sequence on each of
its distal γ-modules. In their classic study of the interactions between human growth
hormone and its receptor’s extracellular binding domain, Cunningham and Wells (67)
demonstrated by SPR that blocking formation of dimeric receptor–ligand complexes
increased the dissociation rate constant from < 10−5 to ~4 × 10−4 s−1. Similarly, Duan et al.
(68) reported minimal dissociation for a pentameric monobody bound to the αvβ3 integrin,
while a single-domain construct dissociated at least 100-fold faster. However, our fibrinogen
binding kinetic data were not influenced by the integrin capture level (Figure S2 of the
Supporting Information), and fitting them to a bivalent analyte model yielded no significant
improvement in the goodness of fit (Table S1 of the Supporting Information); therefore, we
Hantgan et al. Page 8













conclude that fibrinogen binding to multiple immobilized integrins did not make a
significant contribution to our findings.
Alternatively, several lines of evidence indicate that while fibrinogen shares a zwitterionic
binding motif with eptifibatide (10), its macromolecular multidomain structure provides
additional binding sites that may stabilize its complex with αIIbβ3. In addition to
fibrinogen’s primary integrin-recognition motif, γ400–411, auxiliary integrin binding sites
have been localized to γ316–322 (42–44) and γ370–381 (45, 46). Likewise, mutagenesis
studies have identified a cluster of residues critical to fibrinogen binding in the cap
subdomain of αIIb’s β-propeller region (69, 70) and on β3’s specificity-determining loop (9,
71).
The extensive area capable of encompassing these putative contacts between αIIbβ3’s
ectodomain and fibrinogen’s γC module may well be responsible for the longevity of the
integrin–fibrinogen complex. This concept is supported by our observation (Figure S5 of the
Supporting Information) of relatively slow dissociation rates, even for αIIbβ3’s interactions
with echistatin, a 49-residue disintegrin with a single RGD site (47). Echistatin’s nine-
residue carboxy-terminal segment may provide additional contacts that contribute to the
stability of its complex with αIIbβ3, and similar mechanisms may stabilize fibrinogen
binding. Indeed, we only observed rapid dissociation of αIIbβ3 from cHarGD, a monovalent
cyclic peptide integrin antagonist (72).
Physiological Regulation of Integrin Activation
We recognize the challenges in extrapolating from a well-characterized receptor–ligand
system to an environment of densely packed αIIbβ3 receptors with their extracellular
domains protruding from a platelet surface, linked through transmembrane segments to
distant cytoplasmic domains. Recent advances in cell biology, biochemistry, biophysics, and
structural biology have demonstrated how integrin-associated proteins, especially talin and
kindlins, control the receptor’s activation state through interactions with β3’s cytodomain,
the phospholipid bilayer, and the actin cytoskeleton (6, 7, 73, 74). Our model system is not
designed to address the multiplicity of these protein–protein and protein–lipid interactions.
Conversely, because cytodomain separation has emerged as a hallmark of integrin activation
(6, 7, 75), our immunocapture of αIIbβ3 through its αIIb carboxy terminus may stabilize the
receptor’s primed conformation, replicating mechanisms that regulate binding to its primary
physiological ligand, fibrinogen.
CONCLUSIONS
We demonstrated that fibrinogen’s interactions with the αIIbβ3 integrin are dynamically
regulated by priming-induced conformational changes in the receptor’s ectodomain. Our
studies with recombinant fibrinogen, coupled with structural insights, support the postulate
that the stability of the integrin–fibrinogen complex depends on electrostatic interactions
between an aspartate residue on the carboxy terminus of fibrinogen’s γ-module and the β3
subunit’s MIDAS Mg2+ ion. Our equilibrium and transition-state thermodynamic analyses
suggest that locking the initially flexible integrin targeting segment into a binding-competent
conformation requires overcoming a substantial entropy barrier. Only then can the enthalpy-
favorable, long-lived integrin–fibrinogen complex be assembled. We speculate that kinetics
and thermodynamics interact to localize the initiating events in hemostasis to vascular injury
sites.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kinetics of binding of fibrinogen to αIIbβ3 determined by surface plasmon resonance. (A)
Schematic of integrin immunocapture on a biosensor surface, followed by reversible
fibrinogen binding. (B) SPR kinetic traces depicting the time course of concentration
dependent binding of fibrinogen to eptifibatide-primed αIIbβ3. The following fibrinogen
concentrations were used: 5 (black), 10 (red), 20 (green), 50 (yellow), 100 (blue), and 150
nM (pink). The weakened signals at 100 and 150 nM fibrinogen were caused by less
efficient integrin capture in the later cycles of this experiment. Solid lines were determined
by fitting the data to a 1:1 reversible binding model; residuals are shown in the top panel.
The fitting routine also has a term that accounts for the small, sharp drop in RU at the start
of the dissociation step. This effect is due to a slight difference in the refractive index in
sample vs running buffer. No fibrinogen binding was detected with resting αIIbβ3 [empty
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symbols for 5 (black) and 150 nM (pink); data from other concentrations omitted for the
sake of clarity]. All data were collected at 37 °C.
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Inhibition of binding of fibrinogen to αIIbβ3 by eptifibatide and HHLGGAKQAGDV γC
peptide. To facilitate comparison between experiments, SPR kinetic traces are presented as
the ratio of the fibrinogen binding signals to those for αIIbβ3 immunocapture: (empty
squares) 100 nM fibrinogen binding control, (yellow triangles) 100 nM fibrinogen and 300
nM γC peptide, (orange triangles) 100 nM fibrinogen and 3000 nM γC peptide, (blue
circles) 100 nM fibrinogen and 10 nM eptifibatide, and (green circles) 100 nM fibrinogen
and 100 nM eptifibatide. All data were collected at 37 °C.
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Kinetics of binding of recombinant fibrinogen to primed αIIbβ3 determined by surface
plasmon resonance. (A) SPR kinetic traces depicting the time course of concentration-
dependent binding of normal recombinant fibrinogen (10, 30, and 100 nM) to eptifibatide-
primed αIIbβ3 (filled symbols). Solid lines were determined by global fitting of the
complete data set (three experiments and eight fibrinogen concentrations) to a 1:1 reversible
binding model; residuals are shown in the top panel. No binding was detected with rFgn
γΔ408–411 (empty symbols). All data were collected at 37 °C. (B) SPR kinetic traces
showing eptifibatide inhibition of binding of recombinant fibrinogen to primed αIIbβ3.
Normal recombinant fibrinogen (30 nM, red circles) and eptifibatide (26 µM, empty circles).
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Note the complete inhibition. rFgn γΔ408–411 (30 nM, dark red triangles) and eptifibatide
(26 µM, empty triangles). Note the similar negative RU traces in both cases.
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Temperature dependence of the kinetics of fibrinogen binding to primed αIIbβ3 determined
by surface plasmon resonance. To facilitate comparison between experiments, SPR kinetic
traces are presented as the ratio of the fibrinogen binding signals (5, 10, 20, 50, 100, and 150
nM) to those for αIIbβ3 immunocapture. Solid lines were determined by fitting the data in
duplicate experiments to a 1:1 reversible binding model; residuals are presented in the top
panels. The empty symbols denote the inhibitory effects of excess eptifibatide (26 µM) on
binding of 100 nM fibrinogen.
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Equilibrium and transition-state thermodynamic analyses of binding of fibrinogen to primed
αIIbβ3. (A) van’t Hoff analysis of the temperature dependence of the equilibrium
dissociation constants for αIIbβ3–fibrinogen complexes. The solid line was determined by
linear regression. Enthalpy (ΔH°) and entropy (ΔS°) changes for αIIbβ3–fibrinogen binding
were determined from the regression line’s slope and intercept, respectively (47). (B) Eyring
analysis of the temperature dependence of the forward and reverse rate constants for αIIbβ3–
fibrinogen complexes. Data are presented as the logarithm of the association rate, ka data,
divided by the kelvin temperature, and scaled by the ratio of Planck’s constant, h, to
Boltzmann’s constant, kb, plotted vs 1/T (●). The activation enthalpy (ΔHa°‡) and entropy
(ΔSa°‡) were calculated from the slope and intercept, respectively, of the solid line,
determined by linear regression, as described previously (47). Analogous procedures for the
dissociation rate constant, kd (■ with dashed line), yielded ΔHd°‡ and ΔSd°‡.
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Free energy profile for αIIbβ3–fibrinogen complexes. Changes in free energy, enthalpy, and
entropy are depicted along the path from reactants to products. Note that binding requires
overcoming an entropy-dominated transition-state barrier before an enthalpy-stabilized
receptor–ligand complex is reached.
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Integrin–ligand binding modes. Fibrinogen’s γC peptide (green backbone) and eptifibatide
(yellow backbone) occupy similar positions in αIIbβ3’s ligand-binding crevice. αIIb and β3
polypeptides are shown as blue and red ribbons, respectively; highlighted atoms shown in
ball-and-stick representation are color-coded as follows: red for oxygen and blue for
nitrogen. In both cases, a ligand aspartate forms an electrostatic contact with the β3
subunit’s MIDAS Mg2+ (highlighted by the blue-dashed ellipse). Additional stabilization is
provided by a tight turn that enables the γC lysine’s ζN+ atom to form a salt bridge with a
carboxylate anion on αIIb’s Asp224; the ηN+ atom on eptifibatide’s homoarginine makes a
similar contact (highlighted by a red-dashed ellipse). This figure was prepared with Pymol
(76) and is based on crystal structure data presented by Springer et al. (10) for complexes
formed between αIIbβ3’s ectodomain and fibrinogen’s γC peptide (Protein Data Bank entry
2VDO) and eptifibatide (Protein Data Bank entry 2VDN).
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